Skip to main content

Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease

Digestive Diseases and Sciences volume 64, pages 1938–1944 (2019)Cite this article

Abstract

Background

Preclinical data demonstrate that activation of the renin–angiotensin system (RAS) contributes to mucosal inflammation, and RAS inhibition by angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) improves colitis in animal models. Less is known regarding the effects of RAS inhibition on clinical outcomes in inflammatory bowel disease (IBD) patients.

Aim

Evaluate the impact of ACEI and ARB on clinical outcomes in IBD.

Methods

Rates of IBD-related hospitalizations, operations, and corticosteroid use were evaluated retrospectively in two groups. First, 111 IBD patients taking an ACEI or ARB were compared to nonusers matched 1:1 based on sex, age, diagnosis, disease location, and hypertension diagnosis. Second, outcomes in a cohort of 130 IBD patients were compared prior to and during ACEI/ARB exposure.

Results

Compared to matched controls, all IBD patients together with ACEI/ARB exposure had fewer hospitalizations (OR 0.26, p < 0.01), operations (OR 0.08, p = 0.02), and corticosteroid prescriptions (OR 0.5, p = 0.01). Comparing outcomes before and during ACEI/ARB use, there were no differences in hospitalizations, operations, or corticosteroid use for all IBD patients together, but patients with UC had increased hospitalizations (0.08 pre- vs. 0.16 during ACEI/ARB exposure, p = 0.03) and decreased corticosteroid use (0.24 pre-ACEI/ARB vs. 0.12 during ACEI/ARB exposure, p < 0.01) during ACEI/ARB use.

Conclusions

IBD patients with ACEI/ARB exposure had fewer hospitalizations, operations, and corticosteroid use compared to matched controls. No differences in outcomes were observed in individuals on ACEI/ARB therapy when compared to a period of time prior to medication exposure.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21:20–27.

    Article  CAS  PubMed  Google Scholar 

  2. Ruiz-Ortega M, Ruperez M, Lorenzo O, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl. 2002;62:S12–S22.

    Article  Google Scholar 

  3. Fukuzawa M, Satoh J, Sagara M, et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology. 1997;36:49–55.

    Article  CAS  PubMed  Google Scholar 

  4. Mizushima T, Sasaki M, Ando T, et al. Blockage of angiotensin II type 1 receptor regulates TNF-alpha-induced MAdCAM-1 expression via inhibition of NF-kappaB translocation to the nucleus and ameliorates colitis. Am J Physiol Gastrointest Liver Physiol. 2010;298:G255–G266.

    Article  CAS  PubMed  Google Scholar 

  5. Tanida S, Mizoshita T, Mizushima T, et al. Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease. J Clin Biochem Nutr. 2011;48:112–116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Jaszewski R, Tolia V, Ehrinpreis MN, et al. Increased colonic mucosal angiotensin I and II concentrations in Crohn’s colitis. Gastroenterology. 1990;98:1543–1548.

    Article  CAS  PubMed  Google Scholar 

  7. Wengrower D, Zanninelli G, Zannineli G, et al. Prevention of fibrosis in experimental colitis by captopril: the role of tgf-beta1. Inflamm Bowel Dis. 2004;10:536–545.

    Article  PubMed  Google Scholar 

  8. Koga H, Yang H, Adler J, Zimmermann EM, Teitelbaum DH. Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: development of a unique mode of treatment. Surgery. 2008;144:259–268.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Byrnes JJ, Gross S, Ellard C, Connolly K, Donahue S, Picarella D. Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. Inflamm Res. 2009;58:819–827.

    Article  CAS  PubMed  Google Scholar 

  10. Okawada M, Koga H, Larsen SD, et al. Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis. Dig Dis Sci. 2011;56:2553–2565.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sueyoshi R, Ignatoski KMW, Daignault S, Okawada M, Teitelbaum DH. Angiotensin converting enzyme-inhibitor reduces colitis severity in an IL-10 knockout model. Dig Dis Sci. 2013;58:3165–3177.

    Article  CAS  PubMed  Google Scholar 

  12. Lee C, Chun J, Hwang SW, Kang SJ, Im JP, Kim JS. Enalapril inhibits nuclear factor-κB signaling in intestinal epithelial cells and peritoneal macrophages and attenuates experimental colitis in mice. Life Sci. 2014;95:29–39.

    Article  CAS  PubMed  Google Scholar 

  13. Arumugam S, Sreedhar R, Thandavarayan RA, et al. Telmisartan treatment targets inflammatory cytokines to suppress the pathogenesis of acute colitis induced by dextran sulphate sodium. Cytokine. 2015;74:305–312.

    Article  CAS  PubMed  Google Scholar 

  14. Guerra GCB, Araújo AA, Lira GA, et al. Telmisartan decreases inflammation by modulating TNF-α, IL-10, and RANK/RANKL in a rat model of ulcerative colitis. Pharmacol Rep. 2015;67:520–526.

    Article  CAS  PubMed  Google Scholar 

  15. Nagib MM, Tadros MG, ElSayed MI, Khalifa AE. Anti-inflammatory and anti-oxidant activities of olmesartan medoxomil ameliorate experimental colitis in rats. Toxicol Appl Pharmacol. 2013;271:106–113.

    Article  CAS  PubMed  Google Scholar 

  16. Arab HH, Al-Shorbagy MY, Abdallah DM, Nassar NN. Telmisartan attenuates colon inflammation, oxidative perturbations and apoptosis in a rat model of experimental inflammatory bowel disease. PLoS ONE. 2014;9:e97193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Shi Y, Liu T, He L, et al. Activation of the renin–angiotensin system promotes colitis development. Sci Rep. 2016;6:27552.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bataller R, Ginès P, Nicolás JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149–1156.

    Article  CAS  PubMed  Google Scholar 

  19. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997;29:1947–1958.

    Article  CAS  PubMed  Google Scholar 

  20. Rüster C, Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol. 2011;22:1189–1199.

    Article  CAS  PubMed  Google Scholar 

  21. Corey KE, Shah N, Misdraji J, et al. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009;29:748–753.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Bettenworth D, Rieder F. Medical therapy of stricturing Crohn’s disease: what the gut can learn from other organs—a systematic review. Fibrogenesis Tissue Repair. 2014;7:5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Couluris M, Kinder BW, Xu P, Gross-King M, Krischer J, Panos RJ. Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung. 2012;190:523–527.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:2512–2517.

    Article  CAS  PubMed  Google Scholar 

  25. Gross O, Schulze-Lohoff E, Koepke M-L, et al. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transpl. 2004;19:1716–1723.

    Article  CAS  Google Scholar 

  26. Wengrower D, Zanninelli G, Latella G, et al. Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. Can J Gastroenterol. 2012;26:33–39.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

National Institute of Diabetes and Digestive and Kidney Diseases, Grant Number P30 DK42086 and National Institutes of Health, Grant Number K08 DK090152 (JP).

Author information

Affiliations

  1. Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, WA, USA

    Jeffrey D. Jacobs

  2. Department of Medicine, University of Chicago, Chicago, IL, USA

    Thomas Wagner

  3. Center for Research Informatics, University of Chicago, Chicago, IL, USA

    George Gulotta

  4. Department of Public Health Sciences, University of Chicago, Chicago, IL, USA

    Chuanhong Liao

  5. Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, 900 East 57th St., MB #9, Chicago, IL, 60637, USA

    Yan Chun Li, Marc Bissonnette & Joel Pekow

Authors
  1. Jeffrey D. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George Gulotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chuanhong Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan Chun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marc Bissonnette
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joel Pekow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel Pekow.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jacobs, J.D., Wagner, T., Gulotta, G. et al. Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease. Dig Dis Sci 64, 1938–1944 (2019). https://doi.org/10.1007/s10620-019-5474-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-5474-4

Keywords

  • RAS inhibition
  • Angiotensin-converting-enzyme inhibitor
  • Angiotensin receptor blocker
  • Inflammatory bowel disease